Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jclinane.2022.110689 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on efficacy, safety, and tolerability of Lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.
Indian J Ophthalmol
January 2025
Department of Ophthalmology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed to be University), Pillayarkuppam, Pondicherry, India.
The validity and reliability of the Indonesian version of the Diabetes Mellitus Self-Efficacy Scale (DMSES-I).
J Res Nurs
December 2024
Associate Professor, Department of Pediatric and Maternity Nursing, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Background: The incidence of diabetes mellitus (DM) and its complications is increasing in Indonesia. The patient's quality of life will decrease due to this condition. Diabetes self-management is a viable tactic for improving quality of life and reducing blood sugar levels.
View Article and Find Full Text PDFThe Efficacy of Chaihu-Guizhi-Ganjiang Decoction on Chronic Non-Atrophic Gastritis with Gallbladder Heat and Spleen Cold Syndrome and Its Metabolomic Analysis: An Observational Controlled Before-After Clinical Trial [Response to Letter].
Drug Des Devel Ther
December 2024
Department of Pharmacy, Changzheng Hospital, Naval Medical University, Shanghai, People's Republic of China.
Comment on 'Musculoskeletal Ultrasound Assessment of the Clinical Efficacy of the Combination of Acupressure and "Three Methods of Neck Movement (TCM)" Therapy in the Treatment of Cervical Spondylosis: A Study Protocol for a Randomized Controlled Trial' [Response to Letter].
J Pain Res
December 2024
Massage Department, Zhejiang Hospital, Hangzhou City, People's Republic of China.
Xanomeline/Trospium Chloride: First Approval.
Drugs
December 2024
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Xanomeline/trospium chloride (COBENFY™), formerly KarXT, is a first-in-class, oral, fixed-dose muscarinic agonist/antagonist combination being developed for use in schizophrenia and Alzheimer's disease psychosis. Xanomeline is thought to confer efficacy by acting as an agonist at M and M muscarinic acetylcholine receptors in the brain, and trospium chloride reduces the peripheral cholinergic adverse events associated with xanomeline. Xanomeline/trospium chloride received its first approval on 26 September 2024 in the USA for the treatment of schizophrenia in adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!